Lineage Cell Therapeutics (LCTX) EPS (Diluted) Growth (1y) (2015 - 2026)
Lineage Cell Therapeutics (LCTX) EPS (Diluted) Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17,091.12% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 61.58% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -7.16% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 114.31% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn | 38.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.84% |
| Dec 31, 2025 | -55.82% |
| Sep 30, 2025 | -418.21% |
| Jun 30, 2025 | -222.76% |
| Mar 31, 2025 | 15.98% |
| Dec 31, 2024 | 40.54% |
| Sep 30, 2024 | 61.18% |
| Jun 30, 2024 | -0.25% |
| Mar 31, 2024 | -38.50% |
| Dec 31, 2023 | 26.66% |
| Sep 30, 2023 | -14.40% |
| Jun 30, 2023 | 23.67% |
| Mar 31, 2023 | 99.94% |
| Dec 31, 2022 | 77.72% |
| Sep 30, 2022 | 23.44% |
| Jun 30, 2022 | 99.87% |
| Mar 31, 2022 | -458,211.28% |
| Dec 31, 2021 | -2,646.71% |
| Sep 30, 2021 | 11.84% |
| Jun 30, 2021 | -69,823.05% |